MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024
- Matinas BioPharma Hldgs (NYSEMKT: MTNB ) just reported results for the first quarter of 2024. Matinas BioPharma Hldgs reported earnings per share of -3 cents.
- 05/09/2024
|
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners Operator Welcome, everyone, to the Matinas BioPharma First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
- 05/09/2024
|
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
- Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025
- 05/09/2024
|
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
- BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
- 05/02/2024
|
Matinas BioPharma Prices $10 Million Registered Direct Offering
- BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 33,333,334 shares of common stock, at a combined offering price of $0.30 per share and accompanying warrant, pursuant to a registered direct offering. The warrants will have an exercise price of $0.35 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance.
- 04/03/2024
|
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
- 03/28/2024
|
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
- Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions
- 03/27/2024
|
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
- Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
- 03/25/2024
|
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
- BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces complete clinical response in three patients with serious invasive fusarium infection following treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. All three patients were enrolled in the Company's Compassionate/Expanded Use Access Program and were treated by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.
- 03/22/2024
|
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
- BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced that on March 21, 2024, the Company received written notification from the NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to the low selling price of its common stock as described in Section 1003(f)(v) of the NYSE American Company Guide due to shares of its common stock demonstrating sustained price improvement.
- 03/22/2024
|
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
- ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options
- 02/20/2024
|
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
- In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores
- 12/27/2023
|
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
- Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA
- 12/21/2023
|
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
- 11/08/2023
|
Penny Stocks To Buy Now? 3 to Watch With Big News
- Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
- 11/07/2023
|
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
- Study results show reduction in tumor size comparable to IV docetaxel and no systemic toxicity Study results show reduction in tumor size comparable to IV docetaxel and no systemic toxicity
- 11/07/2023
|
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
- Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.
- 10/12/2023
|
Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
- BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces complete clinical resolution of a patient's recurrent hemorrhagic cystitis due to Candida krusei (C. krusei), a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. This patient was treated under Matinas' Expanded Access/Compassionate Use Program by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.
- 10/11/2023
|
Matinas BioPharma to Present at Two Investment Conferences in October 2023
- BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
- 09/28/2023
|
Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
- BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its proprietary lipid nanocrystal (LNC) platform technology, announces that MAT2203, its oral LNC formulation of amphotericin B (AMB), will be featured in an oral company pipeline presentation at IDWeek, being held October 11-15 at the Boston Convention and Exhibition Center.
- 09/27/2023
|
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
- BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
- 09/06/2023
|
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
- BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report second quarter 2023 financial results after market close on Wednesday, August 9, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
- 07/26/2023
|
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
- BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern time. The conference is being held at the New York Hilton Midtown.
- 05/11/2023
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
- 05/10/2023
|
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
- BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
- 05/03/2023
|
7 Small-Cap Biotech Stocks with Massive Potential
- While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.
- 04/27/2023
|
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Jody Cain - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Matkovits - Chief Development Officer Conference Call Participants Greg Fraser - Truist Securities Operator Greetings and welcome to the Matinas BioPharma 2022 Fourth Quarter and Full Year Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
- 03/15/2023
|
Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023
- BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report 2022 financial results after market close on Wednesday, March 15, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
- 03/08/2023
|
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2022 Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Ankit Bhargava - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Thomas Hoover - Chief Business Officer Conference Call Participants Greg Fraser - Truist Robert Hazlett - BTIG Sahil Kazmi - B. Riley Securities Operator Welcome to the Matinas BioPharma Third Quarter 2022 Results Conference Call.
- 11/02/2022
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2022
|
10 Top Penny Stocks To Buy For Uner $1 Right Now
- Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/21/2022
|
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
- BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerome D. Jabbour, Chief Executive Officer of Matinas BioPharma, will present at the ThinkEquity Investment Conference on Wednesday, October 26, 2022, at 10:30 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental Hotel in New York City.
- 10/21/2022
|
Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
- Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial
- 10/12/2022
|
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)
- Matinas Biopharma Holdings, Inc. (MTNB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 08/30/2022
|
Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q2 2022 Results - Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Representative Jerry Jabbour - Chief Executive Officer Dr. Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer Dr. Raphael Mannino - Chief Scientific Officer Dr. Terry Ferguson - Chief Medical Officer Thomas Hoover - Chief Business Officer Conference Call Participants Bert Hazlett - BTIG Operator Hello. And welcome to the Matinas BioPharma Second Quarter 2022 Results Conference Call.
- 08/11/2022
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022
- BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced the Company will host a conference call and live audio webcast on Thursday, August 11, 2022 at 8:30 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2022.
- 07/28/2022
|
Matinas BioPharma to Present at the LD Micro Invitational XII Conference
- BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerry Jabbour, Chief Executive Officer, has been invited to present at the LD Micro Invitational XII Conference on Tuesday, June 7, 2022, at 3:30 p.m. ET (12:30 p.m. PT). The conference is being held at the Four Seasons Hotel in Westlake Village, Calif.
- 05/31/2022
|
Matinas BioPharma (MTNB) CEO, Jerome Jabbour on Q1 2022 Results - Earnings Call Transcript
- Matinas BioPharma Holdings Inc. (NYSE:MTNB ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Peter Vozzo - Investor Relations Conference Call Participants Bert Hazlett - BTIG Operator Welcome to the Matinas BioPharma first quarter 2022 results conference call. At this time, all participants are in a listen-only mode.
- 05/12/2022
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022
- BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced the Company will host a conference call and live audio webcast on Thursday, May 12, 2022 at 8:30 a.m. ET to discuss operational and financial results for the first quarter ended March 31, 2022.
- 05/05/2022
|
Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
- BEDMINSTER, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerry Jabbour, Chief Executive Officer, has been invited to present at the 12th Annual BioNJ BioPartnering Conference, co-sponsored by J.P. Morgan and J&J Innovation, being held virtually May 9-13, 2022.
- 05/03/2022
|
Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
- BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology. The companies will collaborate on.
- 04/11/2022
|
Matinas BioPharma to Present at the Needham Virtual Healthcare Conference
- BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerry Jabbour, Chief Executive Officer, has been invited to present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022, at 3:00 p.m. ET.
- 04/06/2022
|
5 Penny Stocks To Buy According To Analysts With Targets Up To 156%
- Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/16/2021
|
Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q3 2021 Results - Earnings Call Transcript
- Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2021
|
5 Penny Stocks to Watch That Exploded Today, What You Need to Know
- These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/23/2021
|
Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
- BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
- 09/14/2021
|
Matinas BioPharma Stock Jumps After Meningitis Candidate Data
- Matinas BioPharma Holdings Inc (NYSE: MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
- 09/13/2021
|
Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
- – Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 –
- 09/13/2021
|
Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
- Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio
- 08/16/2021
|
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q2 2021 Results - Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q2 2021 Results - Earnings Call Transcript
- 08/10/2021
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2021
|
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
- – Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021 –
- 08/10/2021
|
Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
- BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET. The Company will also host investor meetings during the conference.
- 08/03/2021
|
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021
- BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021.
- 07/27/2021
|
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts
- Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/13/2021
|
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q1 2021 Results - Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -67.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2021
|
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
- – Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from second cohort anticipated Q3 2021 –
- 05/10/2021
|
Matinas BioPharma Hldgs's Earnings: A Preview
- Matinas BioPharma Hldgs (AMEX:MTNB) announces its next round of earnings this Monday, May 10. Here is Benzinga's everything-that-matters guide for this Monday's Q1 earnings announcement.
- 05/07/2021
|
Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
- BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the 7th Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 11:20 a.m. ET. The Company will also host investor meetings during the conference.
- 04/28/2021
|
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
- BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the first quarter ended March 31, 2021.
- 04/27/2021
|
Matinas BioPharma to Present at the Needham Healthcare Conference
- BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 p.m. ET. The Company will also host investor meetings during the conference.
- 04/08/2021
|
Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q4 2020 Results - Earnings Call Transcript
- Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q4 2020 Results - Earnings Call Transcript
- 03/29/2021
|
Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
- – Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics –
- 03/29/2021
|
Matinas BioPharma to Present at the Barclays Global Healthcare Conference
- BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 4:45 p.m. ET. The Company will also host investor meetings during the conference.
- 03/01/2021
|
Why Matinas BioPharma Stock Crashed Today
- The company reported disappointing clinical results.
- 02/01/2021
|
Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®
- – LYPDISO ™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa ® –
- 02/01/2021
|
Matinas: Learning From Amarin's Mistakes
- Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline.
- 01/06/2021
|
Why Matinas BioPharma Holdings Shot Almost 28% Higher Today
- The proposed brand name for its leading pipeline drug got an important nod.
- 01/04/2021
|
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead's Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology
- BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that they plan to collaborate with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to test oral formulations of remdesivir in preclinical models. Remdesivir is owned by Gilead Sciences, Inc. (Nasdaq: GILD) and the lipid nanocrystal (LNC) platform is owned by Matinas. Any product generated as a part of efforts by Matinas and NIAID would require a license from Gilead for the use of remdesivir and a license from Matinas for the use of the LNC formulation.
- 12/07/2020
|
Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders
- - Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -
- 12/07/2020
|
Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer
- – Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules – – Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules –
- 12/01/2020
|
Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients
- BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that it has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF). The award will support preclinical development of MAT2501, Matinas' lipid nano-crystal (LNC) oral formulation of the broad-spectrum aminoglycoside amikacin, toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF).
- 11/20/2020
|
Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
- BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been invited to participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020. The Company will also host investor meetings during the conference.
- 11/19/2020
|
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2020 Results - Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2020 Results - Earnings Call Transcript
- 11/06/2020
|
Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights
- EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort
- 11/06/2020
|
BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma
- BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies. UroGen flunks Phase 2 RTGel combo study.
- 08/30/2020
|
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Lags Revenue Estimates
- Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
Matinas BioPharma Reports Second Quarter 2020 Financial Results and Operational Highlights
- – ENHANCE-IT study of MAT9001 against Vascepa® expected to be fully enrolled in August 2020; topline data anticipated Q1 2021 – – EnACT study of MAT2203 in cryptococcal meningitis resumed enrollment; on track for potential cohort progression Q4 2020 –– Management to host conference call today, Monday, August 10th, at 4:30 p.m. ET –BEDMINSTER, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020, along with a corporate update and outlook for 2020.“We are pleased to announce that both the ENHANCE-IT study of MAT9001 and the EnACT study of MAT2203 have resumed rapid enrollment after a temporary pause due to the COVID-19 pandemic,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. “We continued meaningful progress across our business in the first half of 2020, despite challenging circumstances and conditions. As we look ahead to the second half of 2020 and into 2021, we are well positioned and approaching a number of important catalysts and milestones for the Company and our lead product candidates. We expect potential cohort progression in EnACT in the fourth quarter of this year and topline data from ENHANCE-IT in the first quarter of 2021. In addition, our team continues to advance our key collaborations with our partners applying our LNC platform, as well as identifying opportunities and advancing discussions on potential new applications for this promising and unique delivery technology.”MAT9001 Program Update (next generation, prescription-only omega-3 fatty acid-based composition under development for treatment of cardiovascular and metabolic conditions, including hypertriglyceridemia) * Rapidly approaching completion of enrollment in ENHANCE-IT (Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a second head-to-head comparative study of MAT9001 vs. Vascepa. Enrollment resumed in early June after having temporarily paused in the first quarter of 2020 due to the COVID-19 pandemic. The Company expects to complete enrollment in ENHANCE-IT in August and have topline data available in the first quarter of 2021. * The Company remains on track to meet with the U.S. Food and Drug Administration (FDA) in an End-of-Phase 2 meeting. During this meeting, the Company will discuss data from the completed comparative clinical bridging bioavailability study and 90-day comparative toxicology study to support a potential 505(b)(2) registration pathway. In addition, the Company will review and seek approval for the protocol for a planned Phase 3 trial of MAT9001 in patients with severe hypertriglyceridemia. ENHANCE-IT is an open-label, randomized, 28-day crossover study to assess the pharmacodynamic (PD) effects of MAT9001 vs. Vascepa. The study will enroll approximately 100 adult men and women with elevated triglycerides (150-499 mg/dL), with at least 50% of study subjects with TGs ≥ 200 mg/dL. The study will consist of two 28-day treatment periods, with a washout period of at least 28 days in-between treatments and will be conducted at eight sites in the United States. MAT9001 and Vascepa will each be administered as 2g twice daily with food in accordance with currently approved Vascepa labeling. Measurements of lipid parameters (triglycerides, Total-, LDL-, VLDL-, HDL-, and non-HDL cholesterol, apolipoproteins A1, B and C3, and PCSK9) and omega-3 blood levels will be obtained at each baseline and at the end of each treatment period. The primary endpoint is the percent change from baseline to end-of-treatment in plasma triglycerides.MAT2203 Program Update (orally bioavailable amphotericin B, with targeted delivery, under development for the treatment and prevention of invasive fungal infections, including cryptococcal meningitis) * Enrollment has resumed in the EnACT (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial) study for the treatment of HIV-infected patients with cryptococcal meningitis after temporary suspension by mandate of the Uganda National Drug Authority due to the COVID-19 Pandemic earlier this year. * To date, several patients have been randomized and dosed in the first cohort of 10 patients in the Phase 2 portion of EnACT. The Company expects to make an announcement as to potential progression from the first cohort of patients to the second cohort of 40 patients during the fourth quarter of 2020. More complete data from EnACT could be available in the second half of 2021, depending on the progression of patients through each cohort.EnACT is a Phase 2 open-label, sequential cohort study of approximately 100 patients, financially supported by the National Institutes of Health (NIH), utilizing the Company’s LNC platform delivery technology to orally deliver the traditionally IV-only fungicidal drug, amphotericin B. This study is a prospective, randomized trial evaluating the safety, tolerability and efficacy of MAT2203 in HIV-infected patients with cryptococcal meningitis, compared to treatment with standard IV-administered amphotericin B as induction therapy, and then followed by maintenance treatment with MAT2203.The induction period for all patients will be 14 days, followed by an additional 4 weeks of treatment with MAT2203 during the maintenance period. In total, there will be four cohorts of patients, with each cohort increasing the treatment duration of MAT2203 vs. IV amphotericin B. The first cohort of 10 patients will be administered IV amphotericin for the first five days of the induction period, followed by nine days of oral administration of MAT2203. The primary efficacy endpoint will be measured at Day 14, the last day of the induction period and will include a measure of reduction in fungal count in the cerebral spinal fluid. An independent DSMB will review all data for safety and efficacy and make the recommendation to proceed to the next cohort of patients. Second Quarter 2020 Financial ResultsCash, cash equivalents and marketable securities at June 30, 2020 were approximately $68.0 million, compared to $27.8 million at December 31, 2019. In January 2020, the Company sold an aggregate of 32,260,000 shares of its common stock at a price of $1.55 per share for net proceeds of approximately $46.7 million, after deducting underwriting discounts and commissions and other offering expenses. Based on current projections, the Company continues to believe that cash on hand is sufficient to fund operations into the first half of 2023.For the second quarter of 2020, net loss attributable to common shareholders was $5.8 million, or a net loss of $0.03 per share (basic and diluted), compared to a net loss attributable to common shareholders of $3.6 million, or a net loss of $0.03 per share (basic and diluted) for the same period in 2019. The increase in net loss attributable to common shareholders was due primarily to an increase in operating expenses.Research and development (R&D) expenses for the second quarter of 2020 were $3.4 million, compared to $2.8 million for the same period in 2019. The increase was due primarily to higher clinical development expenses and employee compensation related to the development of MAT9001 and MAT2203.General and administrative (G&A) expenses for the second quarter of 2020 were $2.4 million, compared to $1.8 million in the same period in 2019. The increase was due primarily to higher employee compensation expense associated with increased headcount.*VASCEPA® is a registered trademark of the Amarin group of companies. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results on Monday, August 10, 2020, at 4:30 p.m. ET. To participate in the call, please dial (877) 407-5976 (domestic) or (412) 902-0031 (international). The live webcast will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com) and archived for 60 daysAbout Matinas BioPharmaMatinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors.In addition, the Company is developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on the Company’s proprietary lipid nano-crystal (LNC) platform delivery technology, which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.
- 08/10/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Earnings Preview for Matinas BioPharma Hldgs
- On Monday, August 10, Matinas BioPharma Hldgs (AMEX: MTNB) will release its latest earnings report. Benzinga's outlook for Matinas BioPharma Hldgs is included in the following report.Earnings and Revenue Based on management's projections, Matinas BioPharma Hldgs analysts modeled for EPS of $-0.03 per share on sales of $20.00 thousand. In the same quarter last year, Matinas BioPharma Hldgs also reported EPS at $-0.03 on sales of $89.81 thousand. If the company were to match the consensus estimate when it reports Monday, earnings would not change. Here's how the company's reported EPS has compared to analyst estimates in the past:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -0.03 -0.03 -0.03 -0.03 EPS Actual -0.03 -0.04 -0.03 -0.03 Revenue Estimate 30.00 K 20.00 K 10.00 K 20.00 K Revenue Actual 0 0 0 89.81 K Stock Performance Over the last 52-week period, shares of Matinas BioPharma Hldgs are up 32.91%.View more earnings on MTNBLooking at these results, shareholders should be feeling unsatisfied with these results.Don't be surprised to see the stock move on comments made during its conference call. Matinas BioPharma Hldgs is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/mtnb/mediaframe/37317/indexl.htmlSee more from Benzinga * Earnings Outlook For National Health Investors * Integra Lifesciences Earnings Preview * Earnings Outlook For Kforce(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/07/2020
|
LD Micro--Announces Preliminary List of Presenters for the LD-500.
- LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- 08/05/2020
|
Matinas BioPharma to Participate in the BTIG Virtual Biotech Conference 2020
- BEDMINSTER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat during the BTIG Virtual Biotech Conference 2020 on Tuesday, August 11, 2020 at 9:00 a.m. ET. Mr. Jabbour will also host investor meetings during the conference. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator.A live webcast of the panel discussion will be available on the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com). A webcast replay will be accessible for 90 days following the live presentation.About Matinas BioPharma Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors.In addition, the Company is developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on the Company’s proprietary lipid nano-crystal (LNC) platform delivery technology, which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable. Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.Investor and Media ContactsPeter Vozzo Westwicke 443-213-0505 peter.vozzo@westwicke.comIan Cooney Director – Investor Relations & Corporate Development Matinas Biopharma, Inc. (415) 722-4563 icooney@matinasbiopharma.com
- 08/04/2020
|
Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2020
|
Matinas BioPharma (MTNB) in Focus: Stock Moves 6% Higher
- Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- 07/16/2020
|
Two Sigma Advisers LP Takes Position in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB)
- Two Sigma Advisers LP bought a new stake in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 102,206 shares of the company’s stock, valued at approximately $61,000. Two Sigma Advisers LP owned about 0.05% of Matinas […]
- 07/15/2020
|
3 Healthcare Stocks Under $5 With Triple-Digit Upside Potential
- On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that their financial performances aren’t necessarily the most important piece of the puzzle. Rather, a few key factors like clinical data readouts or regulatory approvals indicate whether or not a particular name will be able to generate sustainable revenues in the long run. As such, any development, good or bad, can act as a catalyst that launches shares in either direct. So, which strategy can help investors find the healthcare stocks poised to blast off on an upward trajectory? One approach is to follow the pros on Wall Street.We used TipRanks’ database to lock in on three healthcare stocks that have been given the Street’s blessing, and come with an affordable price tag. Each ticker trades for less than $5 per share and has earned a “Strong Buy” consensus rating from the analyst community. The icing on the cake? Serious upside potential is on the table. Galmed Pharmaceuticals (GLMD)Focused on the development of its product candidate, Aramchol, Galmed Pharmaceuticals wants to provide patients with a more effective therapy for the treatment of Non-alcoholic Steatohepatitis (NASH). Given its recent addition to its product lineup and its $4.50 share price, the healthcare name is scoring major points with the Street.Back in May, GLMD unveiled Aramchol meglumine, which is an Aramchol salt version that is more soluble than the free acid version, with it also showing improved PK characteristics. The therapy is eligible for New Chemical Entity (NCE) designation and additional patent protection.Weighing in on the impact of this revamp, five-star analyst Yasmeen Rahimi calls the candidate GLMD’s “new star," arguing it “can raise the bar for Aramchol's efficacy in NASH and potentially add a layer of patent protection.” The analyst points out that the company has already placed a significant focus on protecting its intellectual property, with patents maintained in 37 territories in the EU, as well as other countries including Canada, Australia, China and Japan. In addition, patent discussions are taking place in the U.S.Speaking to the improved PK characteristics, Rahimi highlights that when compared to the Aramchol free acid version, Aramchol meglumine produced nearly identical AUCs following a single dose, but a higher AUC after multiple doses, and Meglumine had an identical half-life at both the single and multiple doses. “Importantly, Aramchol meglumine demonstrated three-fold lower variation in concentration during multiple dosing, which hints at a potential for more steady concentrations in patients treated with meglumine and Aramchol meglumine's Cmax was higher during multiple dosing or steady state administration,” the analyst added.As for how COVID-19 affects this trial, Rahimi told clients “GLMD is taking a diligent approach to maintaining execution of Phase 3 ARMOR.” These efforts include temporarily halting the screening of new patients into ARMOR to minimize potential COVID-19 exposure, taking this time to advance the opening of new sites in preparation for when screening and randomization is possible and reducing its costs.To this end, Rahimi rates GLMD a Buy, along with a $33 price target. This figure conveys her confidence in GLMD’s ability to soar 622% in the next twelve months. (To watch Rahimi’s track record, click here)Turning now to the rest of the Street, other analysts also like what they’re seeing. 6 Buys and a single Hold add up to a Strong Buy consensus rating. Given the $19.86 average price target, the upside potential comes in at 334%. (See GLMD stock analysis on TipRanks)ImmunoGen (IMGN)Utilizing antibody-drug conjugates, or ADCs, ImmunoGen hopes its therapies will be able to disrupt the progression of cancer. Ahead of key data readouts, several members of the Street believe that at $4.22, its share price reflects an attractive entry point.Pointing to the FORWARD II study, five-star analyst John Newman, of Canaccord, tells clients that its mirvetuximab asset, which was evaluated in combination with Avastin, generated encouraging results. In addition to exhibiting strong efficacy and safety, a 64% Overall Response Rate (ORR) among Folate Receptor alpha high platinum agnostic patients was witnessed.Newman also noted, “Importantly, mirvetuximab + Avastin demonstrated a 59% ORR for FRa high patients that were platinum resistant, comparing well to ~27-28% for bevacizumab + chemotherapy in a similar population. In addition, ORR was similar between platinum-resistant and platinum-sensitive patients (59% vs 69%), suggesting encouraging efficacy for mirvetuximab in both populations.”As for what these results mean, Newman argues that they suggest mirvetuximab will eventually be approved and used in all lines of ovarian cancer, underscoring the importance of its safety in combination with other drugs.Going forward, enrollment for the Phase 3 MIRASOL trial and Phase 2 SORAYA trial is underway, with top-line data for SORAYA still slated for release in mid-2021. This will be followed up by MIRASOL’s top-line data readout in the first half of 2022.“Importantly, mirvetuximab is known to be a highly active agent in ovarian cancer, which should support robust enrollment. Also, we remind investors that the FORWARD I trial enrolled ahead of schedule in 9 months. We recognize that the COVID-19 pandemic may have some effect on clinical trial enrollment, but we believe the effects can be mitigated,” Newman commented.The analyst is expecting positive data from both trials, with the Phase 2 data potentially supporting accelerated approval and the Phase 3 results supporting full approval. “Importantly, we see multi-leg long-term growth potential for mirvetuximab in ovarian cancer based on expansion into earlier lines of therapy, and eventual combination with platinum therapy in the front-line setting,” he stated.Everything that IMGN has going for it prompted Newman to leave a Buy rating and $12 price target on the stock. Should the target be met, a twelve-month gain of 183% could be in store. (To watch Newman’s track record, click here) Do other analysts agree with Newman? They do. Only Buy ratings, 3, in fact, have been issued in the last three months. At $10.50, the average price target puts the upside potential at 147%. (See ImmunoGen stock analysis on TipRanks)Matinas BioPharma (MTNB)The last healthcare stock on our list, Matinas BioPharma, brings cutting-edge technology to the table, with the goal of developing therapies capable of overcoming the limitations associated with existing options. Even though COVID-19 impacted its clinical activity, multiple analysts believe that its $0.72 share price presents investors with a unique buying opportunity.As a result of the pandemic, the trials for MTNB’s two leading programs, MAT9001 and MAT2203, were delayed. That said, management recently stated it plans to restart the enrollment of ENHANCE-IT for MAT9001 and EnACT for MAT2203. Writing for BTIG, five-star analyst Robert Hazlett noted, “These two programs, especially MAT9001, are core value drivers for Matinas, and trial progress is welcome news.”Looking more closely at the trials, ENHANCE-IT is a head-to-head open-label, 28-day crossover trial featuring patients with elevated triglycerides designed to assess the pharmacodynamic (PD) effects of MAT9001 compared to Amarin’s Vascepa. Hazlett points out that the company has added two additional clinical sites to the program to compensate for the delay.Speaking to the strength of its MAT9001 asset, Hazlett believes the fact that its composition includes DPA, a more potent TG lowering Omega-3, sets it apart from the competition. In addition, the therapy doesn’t increase LDL, with it able to achieve substantially higher blood levels of EPA than Vascepa. “MAT9001’s positioning as a more potent, yet differentiated EPA-based omega 3 has become even more important under the lens of recent Vascepa patent trial challenge... We believe ENHANCE-IT can further differentiate MAT9001, and project material potential for this program, with estimate peak revenue of greater than $1.5 billion,” Hazlett said.As for EnACT, it is an open-label, sequential cohort study evaluating MAT2203, its liposomal nanocrystal (LNC) technology candidate which allows for oral delivery of the potent anti-fungal amphotericin B. It was designed for the treatment of HIV patients with cryptococcal meningitis. “Cryptococcal meningitis represents a beachhead for broader antifungal consideration of MAT2203 over time,” Hazlett commented. It should be noted that the CF Foundation has supported the therapy’s preclinical development, and MTNB has submitted a proposal to receive funding for MAT2501 through Phase 2.To this end, Hazlett rates MTNB a Buy along with a $5 price target. Shares could appreciate by 586%, should the analyst’s thesis play out in the coming months. (To watch Hazlett’s track record, click here) Looking at the consensus breakdown, the rest of the Street agrees with Hazlett’s assessment. With 6 Buys and no Holds or Sells, the word on the Street is that MTNB is a Strong Buy. The $3.29 average price target implies shares could skyrocket 362% in the next year. (See MTNB stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/14/2020
|
State Street Corp Increases Stock Holdings in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB)
- State Street Corp boosted its position in shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) by 658.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,700 shares of the company’s stock after acquiring an additional 110,000 shares during the quarter. State Street Corp owned […]
- 07/05/2020
|
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) * ADC Therapeutics SA (NYSE: ADCT) * Akebia Therapeutics Inc (NASDAQ: AKBA) * Alterity Therapeutics Ltd (NASDAQ: ATHE) (announced agreement with the FDA regarding Phase 2 study of Parkinsonian disorder drug) * Calliditas Therapeutics AB ADR (NASDAQ: CALT) * GENMAB A/S/S ADR (NASDAQ: GMAB) - partner Seattle Genetics, Inc. (NASDAQ: SGEN) announced positive results for antibody-drug conjugate for cervical cancer * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Hologic, Inc. (NASDAQ: HOLX) (reacted to a positive analyst action) * Legend Biotech Corp (NASDAQ: LEGN) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Mersana Therapeutics Inc (NASDAQ: MRSN) * Novavax, Inc. (NASDAQ: NVAX) * Opko Health Inc. (NASDAQ: OPK) * Pacira Biosciences Inc (NASDAQ: PCRX) * Pliant Therapeutics Inc (NASDAQ: PLRX) * ResMed Inc. (NYSE: RMD) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Twist Bioscience Corp (NASDAQ: TWST) (announced launch of Twist Respiratory Virus Research Panel for detecting a range of respiratory diseases) * West Pharmaceutical Services Inc. (NYSE: WST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 30) * Brickell Biotech Inc (NASDAQ: BBI) * Iterum Therapeutics PLC (NASDAQ: ITRM) (announced $5-million registered offering) * Qualigen Therapeutics Inc (NASDAQ: QLGN) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) * VIVUS, Inc. (NASDAQ: VVUS)Stocks In Focus T2 Biosystems Pre-Announces In-Line Q2 Revenues, Launches COVID-19 Test In US T2 Biosystems Inc (NASDAQ: TTOO) announced the U.S. launch of the T2SARS-CoV-2 Panel, its COVID-19 molecular diagnostic test.The test was developed under a license agreement with the Center of Discovery and Innovation at Hackensack Meridian Health and is being commercially distributed after meeting requirements for an Emergency Use Authorization request to the FDA.Separately, the company pre-announced second-quarter results and said it expects revenues of $2.4 million to $2.6 million versus $1.8 million in the year-ago period, while analysts estimate revenues of $2.45 million.The stock was surging 74.8% to $2.22 premarket Wednesday.Akero Reports Positive Results For Midstage NASH Drug Study Akero Therapeutics Inc (NASDAQ: AKRO) announced positive results from a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin in patients with nonalcoholic steatohepatitis.The company said of the 40 treatment responders who had end-of-treatment biopsies, 48% achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity score and 28% achieved at least a two-stage improvement in fibrosis.In addition, 48% of responders achieved NASH resolution with no worsening of fibrosis. Treatment with EFX was generally reported to be well-tolerated, Akero said.The stock was up 45.26% at $36.20 premarket Wednesday.See also: The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week Pfizer, Germany's Merck KGaA Announce FDA Nod For Label Expansion For Cancer Drug Pfizer Inc. (NYSE: PFE) and MERCK KGAA/S ADR (OTC: MKKGY) unit EMD Serono said the FDA approved the sBLA for Bavencio for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.Aravive To Join Russell 2000, 3000 Indexes Aravive Inc (NASDAQ: ARAV) said it has been added to the Russell 2000 and Russell 3000 indexes, effective June 29, as part of the 2020 Russell U.S. indexes reconstitution. The stock added 7.39% to $12.50 in after-hours trading.BeiGene Begins Commercialization of Amgen's Bone Tumor Drug In China Beigene Ltd (NASDAQ: BGNE) said it has begun commercializing Amgen, Inc.'s (NASDAQ: AMGN) Xgeva (denosumab) in China for the treatment of giant cell tumor of bone. This marks the first Amgen product that has been transitioned to BeiGene for commercialization in China since the commencement of the parties' global strategic oncology collaboration in January 2020, Beigene said.Matinas Announces Resumption Of Clinical Studies Following COVID-Induced Pause Matinas BioPharma Holdings Inc (NYSE: MTNB) said it has commenced enrollment and started dosing patients in the ENHANCE-IT study, a head-to-head study of MAT9001 vs. Vascepa.The company expects enrollment to be completed by August and top-line data from the study to be available in the first quarter of 2021.View more earnings on IBBThe company also said it expects to resume dosing patients in the EnACT study imminently, following the recent receipt of necessary governmental and regulatory approvals in Uganda.Both studies temporarily paused enrollment in March due to the COVID-19 pandemic.In premarket trading Wednesday, the stock was adding 3.49% to 80 cents.Earnings Avid Bioservices Inc's (NASDAQ: CDMO) fourth-quarter revenue fell 26% to $12.6 million and the loss per share widened from 2 cents to 11 cents.Analysts had expected a wider loss of 16 cents per share.The company guided fiscal year 2021 revenues to a range of $76 million to $81 million against an $83.85-million consensus estimate.In after-hours trading, the stock advanced 5.56% to $6.93.Offerings Chiasma Inc (NASDAQ: CHMA), which recently received FDA approval for Mycapssa for the treatment of acromegaly, said it has commenced an underwritten public offering of its common stock, and to certain investors, pre-funded warrants to purchase shares of its common stock.All of the securities to be sold in the offering are to be sold by the company. The company said it intends to use the net proceeds primarily for the commercialization of Mycapssa.The stock slipped 14.50% to $4.60 in after-hours trading.Transenterix Inc (NYSE: TRXC) said it has commenced an underwritten offering of common stock. The stock was down 29.78% to 38 cents premarket. Related Link: Gilead Announces Pricing Of Coronavirus Treatment Remdesivir: 'We Believe All Patients Will Have Access'See more from Benzinga * Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/01/2020
|
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 30)
ADC Therapeutics SA (NYSE:...
- 07/01/2020
|
Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials
- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has commenced enrollment and started dosing patients in the ENHANCE-IT study and that it expects to resume dosing patients in the EnACT study imminently, following the recent receipt of necessary governmental and regulatory approvals in Uganda. Both studies had temporarily paused enrollment in March due to the COVID-19 pandemic.
- 06/30/2020
|
Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Up to $0.89
- Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) gapped up prior to trading on Wednesday . The stock had previously closed at $0.95, but opened at $0.89. Matinas BioPharma shares last traded at $0.83, with a volume of 1,260,260 shares traded. A number of research analysts recently commented on MTNB shares. Zacks Investment Research cut Matinas BioPharma from […]
- 06/26/2020
|
Hedge Funds Have Never Been This Bullish On Matinas Biopharma Holdings, Inc. (MTNB)
- In this article we will take a look at whether hedge funds think Matinas Biopharma Holdings, Inc. (NYSE:MTNB) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get […]
- 06/24/2020
|
Matinas BioPharma to Present at the Jefferies Virtual Healthcare Conference
- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview during the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator. A live webcast of the panel discussion will be available on the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com).
- 05/26/2020
|
Insider Buying: The Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Independent Vice Chairman of the Board Just Bought 33% More Shares
- Whilst it may not be a huge deal, we thought it was good to see that the Matinas BioPharma Holdings, Inc...
- 05/19/2020
|
Will Matinas BioPharma Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor of Matinas BioPharma
- 05/18/2020
|
Edited Transcript of MTNB earnings conference call or presentation 11-May-20 8:30pm GMT
- Q1 2020 Matinas BioPharma Holdings Inc Earnings Call
- 05/12/2020
|
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1 2020 Results - Earnings Call Transcript
- Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Peter Vozzo - Investor Relations J
- 05/12/2020
|
Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates
- Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/11/2020
|
Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights
- – ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management.
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2020 Financial and Operational Results on May 11, 2020
- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 4:30 p.m. ET to discuss operational and financial results for the first quarter ended March 31, 2020. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.
- 05/04/2020
|
Matinas BioPharma to Participate in Panel Discussion During Maxim Group Infectious Disease Virtual Conference
- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a panel discussion, as well as host investor meetings, during the Maxim Group Infectious Disease Virtual Conference. Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator, Soraya Dorce (sdorce@maximgrp.com). A live audio webcast of the panel discussion will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com) and at M-Vest.
- 04/28/2020
|
Edited Transcript of MTNB earnings conference call or presentation 9-Mar-20 12:00pm GMT
- Q4 2019 Matinas BioPharma Holdings Inc Earnings Call
- 04/07/2020
|
Investors Who Bought Matinas BioPharma Holdings (NYSEMKT:MTNB) Shares Three Years Ago Are Now Down 81%
- Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So take a moment to...
- 04/02/2020
|
Fly Intel: Pre-market Movers CCO;SQNS;NBL;PEI;CAG;RH;SNDL;DLTR;MTNB;CCL;TWLO
- Fly Intel: Pre-market Movers CCO SQNS NBL PEI CAG RH SNDL DLTR MTNB CCL TWLO
- 03/31/2020
|
Matinas BioPharma Provides Comment on Impact of Vascepa Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs
- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa and also provided an update on the effect of the rapidly evolving COVID-19
- 03/31/2020
|
Fly Intel: Wall Street's top stories at midday TGNA;APO;SOGO;LYV;MTNB;MGIC;OXY;XEC;MRO;APA;FANG;CAT;JPM;DOW;CVX;XOM
- Fly Intel: Wall Street's top stories at midday TGNA APO SOGO LYV MTNB MGIC OXY XEC MRO APA FANG CAT JPM DOW CVX XOM
- 03/09/2020
|
Fly Intel: Pre-market Movers KALA;DHT;SOGO;SOHU;MTNB;MGIC;LYV;BP;CVX;XOM;COP;RDS.A;RDS.B;TOT;OXY;SLB;RIG
- Fly Intel: Pre-market Movers KALA DHT SOGO SOHU MTNB MGIC LYV BP CVX XOM COP RDS.A RDS.B TOT OXY SLB RIG
- 03/09/2020
|
Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
- Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis.
- 03/09/2020
|
Matinas Biopharma Holdings, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 9, 2020 / Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March ...
- 03/09/2020
|
Fly Intel: Wall Street's top stories for Monday DOW;CVX;XOM;JPM;CAT;FANG;APA;MRO;XEC;OXY;AON;WLTW;TWTR;INO;INTU;TGNA;SOGO;LYV;MTNB;MGIC
- Fly Intel: Wall Street's top stories for Monday DOW CVX XOM JPM CAT FANG APA MRO XEC OXY AON WLTW TWTR INO INTU TGNA SOGO LYV MTNB MGIC
- 03/09/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and Xeris Pharmaceuticals (XERS)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Matinas BioPharma (MTNB) and Xeris Pharmaceuticals (XERS)
- 03/06/2020
|
Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®
- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has initiated the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa® in patients with elevated triglycerides (150-499 mg/dL). The ENHANCE-IT study will assess MAT9001’s effectiveness in reducing triglyceride levels and other important lipid markers, as well as gather important data on bioavailability and blood levels of eicosapentaenoic acid (EPA) and other omega-3 fatty acids. “The ENHANCE-IT study is a significant next step in our clinical development program designed to highlight the impressive efficacy of MAT9001 and further distinguish its superior profile from Vascepa,” commented James J. Ferguson, M.D., Chief Medical Officer of Matinas.
- 03/05/2020
|
Matinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board
- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) today announced the appointment of James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA to its Scientific Advisory Board (SAB). Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease.
- 03/04/2020
|
Confounding Decline Creates an Opportunity in Amarin Stock
- Amarin stock has declined by nearly a quarter so far in 2020 on little news. That lower valuation makes AMRN intriguing.
- 02/28/2020
|
Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020
- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, March 9, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2019. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.
- 02/24/2020
|
Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the independent Data Safety Monitoring Board (DSMB) for the EnACT study has completed its planned review of initial safety and tolerability data from the Part 1 dose escalation phase and unanimously approved proceeding with enrollment in the Part 2 efficacy phase at 2g of MAT2203 daily, the highest dose tested in Part 1. The 2g dose will be tested in the 2-week induction phase of treatment. Part 2 of the EnACT study will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.
- 02/19/2020
|
Analysts: These 3 Penny Stocks Are Positioned for Big Gains in 2020
- Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering.However,
- 02/12/2020
|
5 Stocks Under $5 With Colossal Growth Prospects
- Investors want to see a return on investment, it's as simple as that. Regardless of the size of the investment, the end goal remains the same. Sure, there are several ways to go about achieving this objective, yet time after time Wall Street observers circle back to a single tried and true strategy.Growth investing involves identifying the stocks with long-term growth prospects that go above and beyond those of their peers.It should be noted, though, that plays in the growth-stock arena can sometimes come with a price tag to match their huge potential for gains. However, there are compelling names out there that don't cost a fortune.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhile some naysayers might argue that you get what you pay for, others will point out that stocks trading at low levels can represent some of the most compelling names on the Street, with entry points that make them even more attractive. * 7 Stocks to Buy for February Contrarians With this in mind, I used TipRanks' Stock Screener tool during my own search for affordable growth names. After sorting the results by current share price, analyst consensus and price target, the tool revealed three stocks that have received a wealth of support from Wall Street analysts, all under $5 per share. To top it all off, each boasts massive upside potential from current levels. Matinas BioPharma (MTNB)Source: Shutterstock Like the name suggests, Matinas BioPharma Holdings (NYSE MKT:MTNB) is a biopharma focused on the development of lead candidate, MAT9001, its prescription-only omega-3 fatty acid drug for cardiovascular and metabolic conditions. After the FDA approved the label expansion of Amarin's Vascepa drug to include cardiovascular disease patients with high triglycerides of greater than 150 mg/dL, some analysts believe that MTNB's $1.44 share price is a bargain.Piper Sandler analyst Edward Tenthoff tells investors that his bullish thesis is primarily driven by earlier data published by MTNB. Back in 2015, the company reported that during a Phase 1 study, MAT9001 was found to have produced a greater reduction of triglycerides, with the figure coming in at 33% compare to Vascapa's 11%.The drug is currently being evaluated in the Phase 2 ENHANCE-IT study versus Vascepa. With data slated for release in the fourth quarter of this year, big things could be on the way. Tenthoff argues MTNB could start a single Phase 3 severe hypertriglyceridemia trial in 2021 and see potential approval in 2023. In addition, he thinks that the importance of omega-3-based medicines is expanding.All of the above factors prompted the analyst to start his MTNB coverage by publishing an "overweight" rating and setting a $3 price target. Should the target be met, shares could be in for a 108% gain over the next twelve months.Similarly, the rest of the Street takes a bullish approach when it comes to MTNB. Out of four analysts tracking the name over the last three months, 100% see the stock as a "buy," making the consensus rating a "strong buy." Given the $3.25 average price target, the upside potential of 126% surpasses Tenthoff's estimate. See the MTNB stock analysis. Northern Oil And Gas (NOG)Source: Shutterstock Northern Oil and Gas (NYSE MKT:NOG) is one of the primary non-operator franchises in the Bakken and Three Forks plays in the Williston Basin of North Dakota and Montana. Its total footprint, which lands at about 165,000 acres, as well as its proved reserves of 65.3 million barrels of oil equivalent at year-end 2015, has helped cement its status as one of the leading players in the space. Its $1.69 price tag seems almost too good to be true.Back in December, the company gave investors a reason to get excited after it announced that it would start paying out a quarterly dividend. The first dividend will come in at two cents per share, payable in April 2020. In addition, the forward yield lands at 3.14%.This news prompted Imperial Capital analyst Jason Wangler to boost his rating from "in-line" to "outperform." He argues that while the dividend is modest, it demonstrates that NOG has taken steps in the right direction in terms of its balance sheet over the last two years. On top of this, it also means that the name can be thought of as a yield vehicle.It makes sense, then, that in addition to the upgrade, Wangler bumped up the price target from $2 to $2.50. At this new target, the upside potential comes in at 48%. * 7 Under-the-Radar European Stocks to Buy for 2020 When it comes to other analyst activity, it has been relatively quiet on Wall Street. That being said, the two other analysts that published a review in the last three months rated NOG as a "buy," making the Street consensus a "strong buy." Not to mention the $3.25 average price target brings the upside potential to 92%. See the NOG stock analysis. Durect Corporation (DRRX) Source: Shutterstock Durect Corporation (NASDAQ:DRRX) has a simple objective: to transform medicine. It wants to develop drugs that can provide meaningful advances in patient health and wellbeing. At the bargain price of $2.12 per share, analysts warn investors that if they wait too long, they could miss out on the opportunity.While investor concern has definitely emerged, Craig-Hallum analyst Francois Brisebois is still very much on board. Fears among investors have been driven by the company's announcement that the AdCom vote for its Posimir drug's Class 2 New Drug Application (NDA) resubmission was split right down the middle.As a result, Brisebois doesn't assign any value to the drug in the model. Rather, he highlights its DUR-928 candidate for primary alcoholic hepatitis as DRRX's primary value driver, calling early efficacy and safety data incredibly encouraging. On top of this, the analyst argues that the combination of the current poor standard of care and the $3 billion total addressable market played into his conclusion that investors should buy on any weakness.With this in mind, Brisebois kicked off his DRRX coverage by issuing a "buy" rating. In addition, he set a Street high price target of $6, implying a staggering 183% upside potential.Meanwhile, the rest of the Street also likes what it's seeing. A "strong buy" consensus rating breaks down into three "buys" and a single "hold." While less aggressive than that of Brisebois, the $4.65 average price target still puts the potential twelve month gain at 119%. See the DRRX stock analysis. Carrols Restaurant Group (TAST)Source: Shutterstock While the name Carrols Restaurant Group (NASDAQ:TAST) might not ring any bells, but you've probably heard of its restaurants Burger King and Popeyes. It is true that shares took a pretty substantial hit following its preliminary fourth quarter results. Now at just $4.80 apiece, Deutsche Bank's Brian Mullan is still in the restaurant company's corner.The negative reaction came largely as a result of Burger King's same store sales (SSS) results. At 2%, the figure falls well below the implied guidance's range of 4% to 5% range and reflects a deceleration in November and December.However, Mullan tells investors that there's a silver lining. Management noted that the focus will shift towards managing both net leverage levels and free cash flow. "While management wasn't explicit with its plans, reading the tea leaves our sense is that these comments could pertain to either: 1) a reduced pace of acquisitions for the foreseeable future, 2) a potential slowdown in new unit development, or 3) all of the above," he explained.This combined with the new CFO appointment implies that the plans for the above are "… fluid and evolving. We think the key takeaway here is that management is mindful of the market's perception of TAST's net leverage levels, and that it has several options at its disposal to address this, should it see fit," Mullan added.Taking all of this into consideration, the analyst left his "buy" rating and $8 price target as is. This means that shares could potentially surge 67% in the next twelve months. * 7 Biometrics Stocks That Will Help Shape the Next Decade Judging by the consensus breakdown, the rest of the Street is in agreement. With only "buy" ratings assigned in the last three months, the message is clear: TAST is a "strong buy." It also doesn't hurt that the $8.83 average price target suggests 84% upside potential. See the TAST stock analysis. VBI Vaccines (VBIV)Source: Shutterstock VBI Vaccines' (NASDAQ:VBIV) claim to fame is its Sci-B-Vac product, which was the first vaccine to be commercially-approved for hepatitis B. The vaccine is currently available in Israel and ten other countries. It recently completed its Phase 3 program in the U.S., Europe and Canada. After new data was released earlier this month, analysts have been impressed, to say the least.On Jan. 9, the company, which goes for $1.46 a share, announced that Sci-B-Vac had met both its primary and secondary endpoints in the second Pivotal Phase 3 CONSTANT study. Both management and investors were excited by the results as they demonstrate that the candidate is both safe and highly-potent.While this outcome is encouraging, VBIV's potential extends beyond Sci-B-Vac. BMO Capital analyst Do Kim highlights its VBI-1901 and VBI-2601 candidates as potentially driving significant upside. According to the analyst, updated Phase 1/2a tumor response and survival data for VBI-1901's use in glioblastoma multiforme (GMB) is slated for release some time in the first half of 2020. Should the results be favorable, VBIV could develop a modified version to target other EBV+ cancers. On top of this, VBI-2601 proof-of-concept for use in chronic hepatitis B infection (HBV) is expected in the second half of the year.
- 01/31/2020
|
Prospects Appear Bright for Small Drug Industry in 2020
- Prospects Appear Bright for Small Drug Industry in 2020
- 01/21/2020
|
Prospects Appear Bright for Small Drug Industry in 2020
- Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.
- 01/21/2020
|
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel CARA;HZNP;EOLS
- Cara Therapeutics named a BioPharma top pick for 2020 at Stifel Stifel CARA HZNP EOLS
- 01/10/2020
|
